Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1371959 10.3389/fphar.2024.1371959 Pharmacology Systematic Review Efficacy and safety of Danhong injection for treating myocardial infarction: a systematic review and meta-analysis of randomized controlled trials Yang et al. 10.3389/fphar.2024.1371959 Yang Shiyi 1 † Wang Yin 2 † Shen Hailiang 2 Chen Tianhang 1 2 Du Haixia 2 * 1 College of Life Science, Zhejiang Chinese Medical University, Hangzhou, China 2 College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China

Edited by: Weijian Bei, Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China

Reviewed by: Zhitao Feng, China Three Gorges University, China

Changlin Zhai, Jiaxing University, China

Zhouqing He, Guangzhou University of Chinese Medicine, China

 *Correspondence: Haixia Du, duhaixia@zcmu.edu.cn

These authors have contributed equally to this work

 13 06 2024 2024 15 1371959 17 01 2024 24 05 2024 Copyright © 2024 Yang, Wang, Shen, Chen and Du. 2024 Yang, Wang, Shen, Chen and Du

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Objective

Danhong injection (DHI) is widely used in the treatment of myocardial infarction (MI). We aimed to systematically review the efficacy and safety of DHI in a randomized controlled experiment on MI.

 Methods

We searched the randomized controlled trials (RCTs) of DHI for MI published before 2 April 2023 in China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Wanfang database, China Science and Technology Journal Database (VIP), PubMed, Web of Science, Cochrance Library, and Embase databases. The methodological quality of the included studies was evaluated using the Cochrane Handbook 5.3 criteria using the RevMan software, and meta-analysis was performed and a forest map was drawn.

 Results

A total of 38 trials included 3877 patients, including 2022 cases in the DHI treatment group and 1855 cases in the control group. Meta-analysis showed that the total effective rate (RR = 1.18%, 95% CI [1.14–1.12]) during treatment with DHI was higher than that of the control group. The prevalence of cardiac arrhythmia (RR = 0.55%, 95% CI [0.46–0.65]) was lower than that of the control group. The incidence of heart rate failure (RR = 0.45%, 95% CI [0.30–0.70]) was lower than that of the control group. The prevalence of cardiogenic shock (RR = 0.33%, 95% CI [0.11–1.04]) was p > 0.05, and the difference was not statistically significant. There was no statistically significant difference in LVEF between the two groups (MD = 0.00%, 95% CI [0.00–0.00]). CK-MB (MD = −0.81%, 95% CI [−0.92∼ −0.69]) was lower than the control group. hs-CRP (MD = −1.09, 95% CI [−1.22∼ −0.97]) was lower than the control group. The incidence of adverse reactions (RR = 0.37, The 95% CI [0.17–0.82]) was lower than that in the control group.

 Conclusion

Basing on our study, the use of DHI in the treatment of myocardial infarction patients is effective, can improve cardiac function, reduce the incidence of adverse reactions, and improve the overall quality of life.

 Systematic Review Registration

https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023390973.

 Danhong injection myocardial infarction traditional Chinese medicine cardiovascular disease meta-analysis section-at-acceptance Ethnopharmacology Introduction

Myocardial infarction (MI) refers to myocardial ischemia and necrosis, which is a kind of acute and critical illness based on coronary artery disease (Hu et al., 2012). After MI, many serious complications may occur, including muscle rupture, septal compartment, and free wall rupture (Murphy and Goldberg, 2022), as well as malignant arrhythmias such as cardiogenic shock, heart failure, or premature ventricular contractions, etc. MI has a high incidence of acute attacks and a high mortality rate, making it a common cause of death from coronary heart disease (Zhang et al., 2019). In recent years, the age of onset has tended to be younger (Song et al., 2023). According to data released by the National Health Commission, cardiovascular disease (CVD) ranks first in the mortality rate of diseases in China (Yang et al., 2023).

The general treatment methods for MI include coronary intervention (PCI), emergency thrombolytic therapy, elective surgery and drug therapy. However, these treatment methods still have some shortcomings, such as most hospitals using selective PCI in the timing of PCI intervention, but there is a conflict with the treatment principles of ST-elevation myocardial infarction (STEMI) in the timing of intervention (Hu et al., 2023). Due to the increased risk of bleeding, emergency thrombolytic therapy is usually contraindicated in certain conditions. In addition, thrombolysis seems to have little effect on the prognosis of patients with cardiogenic shock or venous graft occlusion (Himbert et al., 1995). At present, the intervention and drug treatment of MI in China have not yet reached a certain level, and the high cost is also a problem. Therefore, there is an urgent need to explore other potentially effective interventions to treat MI.

Traditional Chinese medicine (TCM) believes that the main pathogenesis of MI is heartache, true heartache, and chest paralysis. The treatment method mainly focuses on supplementing qi and promoting blood circulation, and TCM treatment can not only significantly improve clinical symptoms, but also improve objective parameters and increase clinical cure rate (Gao et al., 2018). Danhong injection (DHI), as one of the most popular clinical TCM medications for the treatment of MI, is extracted from Danshen (Salvia miltiorrhiza Bunge) and Safflower (Carthamus tinctorius L.), which are prepared in a ratio of 3:1 (Wang et al., 2022), It has good effects on promoting blood circulation, removing blood stasis, and relieving pain through menstruation. DHI has anti-atherosclerosis, inhibiting platelet aggregation (Li et al., 2022), improving microcirculation, promoting fibrinolysis, and even has a certain anticoagulant effects (Feng et al., 2019). Research has shown that DHI is superior to Western medicine in terms of incidence of adverse cardiac reactions, promotion of reperfusion, improvement of heart function, and protection of myocardium (He et al., 2021). However, there is limited literature review and systematic review on the treatment of MI with DHI, which requires further research.

In this study, we conducted a systematic and comprehensive analysis of relevant randomized controlled trials (RCTs) of DHI treatment for MI through meta-analysis, so as to better verify the efficacy and safety of DHI treatment for MI.

 Methods

This study was conducted following the protocol registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the number CRD42023390973. Our meta-analysis was performed in accordance with the Preferred Reporting Item for Systematic Reviews and Meta-analyses (PRISMA) guidelines (Bernardo, 2017).

Eligibility and exclusion criteria

The randomized controlled trials (RCTs) consistent with the following requirements were taken into our consideration: 1) Languages are limited to Chinese and English. 2) The subjects of the study were MI patients with no age or gender restrictions. 3) In the experimental group, Danhong injection was added to the basic treatment of the control group with 5% glucose solution or 0.9% sodium chloride injection as an intravenous infusion (Dezawa et al., 2019). 4) The control group was treated with conventional treatment, including oxygen inhalation, analgesics, thrombolysis, nitrates, lipid-regulating drug atorvastatin (Hu et al., 2021), β-receptor blocker (Pitcher et al., 2022), antiplatelet aggregation drug ticagrelor (Wang et al., 2018), anticoagulant drug low molecular weight heparin, unfractionated heparin, etc. Research design: randomized controlled trial.

Studies were excluded according to the following criteria: 1) Duplicate publications, and only one of them remains, 2) Reviews, systematic reviews, reviews, animal tests, etc., 3) It is inconsistent with the research content of this paper, 4) The experimental methods do not match, 5) The type of study was non-RCT, cohort study or case-control study, 6) outcome measures were inconsistent, 7) those obvious flaws, such as data duplication or statistical errors, and 8) There is only a summary and no complete article.

 Literature sources and search

Computer search databases: China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Wanfang database, China Science and Technology Journal Database (VIP), PubMed, Web of Science, Cochrance Library, and Embase databases. The included studies were published between the establishment of each database and 2 April 2023. Search terms include “Danhong,” “Danhong Injection” and “Myocardial Infarction”.

 Evaluating indicator

The primary outcome was the total effective rate. The secondary outcomes were the incidence of arrhythmia (Krahn et al., 2022), the incidence of heart rhythm failure, and the incidence of cardiogenic shock; Left ventricular ejection fraction (LVEF) (Bozkurt et al., 2021); Creatine kinase isoenzyme (CK-MB) (Minamidate et al., 2022); Hypersensitive C-reactive protein (hs-CRP) (Kandelouei et al., 2022); Incidence of adverse reactions (ADRs).

 Literature inclusion and data Extraction

The resulting literature library was created using EndNote 9.1 software, and the inclusion of the literature was independently completed by two researchers. If the results were disputed at any stage, a third researcher would be involved in the discussion. In addition, useful data described in detail in all the original studies included in the analysis were extracted, including basic information (author’s name, date of publication, title), detailed characteristics of included patients (sample size, sex, mean age), diagnosis standards, treatment time, intervention measures (drug), outcomes (primary outcome, secondary outcome), and information on the quality of RCTs (Jadad score).

 Risk of bias assessment

Quality assessment was carried out using the Cochrane assessment of risk of bias tool (Higgins et al., 2011), and the quality of all included RCTs was independently assessed by two review authors. Low-risk, high-risk, and unclear risk were assessed based on seven domains: randomization method, concealment of allocation method, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data, selective reporting of study results, and other sources of bias (Whiting et al., 2011; Drucker et al., 2016).

 Statistical analysis

Review Manager 5.3 software was used to create a schematic diagram of the risk assessment of bias and a schematic diagram of the proportion of each item of quality assessment. Forest plots were plotted using RevMan 5.3, and for dichotomous variables, risk ratio (RR) (Talebi et al., 2019) and 95% confidence intervals (95% CI) were used to represent the results of a meta-analysis of total effective rate, incidence of arrhythmias, incidence of heart rate failure, and incidence of cardiogenic shock. For continuous data, the mean difference (MD) and 95% confidence interval (95% CI) were used to represent the meta-analysis results for LVEF, CK-MB, and hs-CRP. Heterogeneity was included in these studies using the X2 test and the value of I2 analysis (Lin et al., 2017). When the 95% CI for RR did not include 1 or the 95% CI for MD did not contain 0, there was a significant difference in the results.

 Results Literature search and basic information

A total of 1005 articles were searched through these databases, and EndNote 9.1 software was used to screen a total of 38 articles in the meta-analysis study, and the screening details are shown in Figure 1. The 38 studies included 3877 patients, including 2022 patients in the Danhong treatment group and 1855 patients in the control group, and the basic information is shown in Table 1.

Flow chart of literature screening.

Basic information of the included studies.

ID Method Object of observation Diagnosis standards Intervention Treatment time Outcomes Jadad score
Total sample (T/C) Sex [T (M/F):C (M/F)] Age (T:C)
Chen and Liu (2013) RCT, Open-blinding 75 (39/36) (21/18): (19/17) (52.3 ± 3.6): (53.1 ± 2.9) UNMIDT (2007 CMA) DHI (30 mL ivgtt qd) 14d TER, ADRs 4
Li et al. (2019) RCT, Open-blinding 90 (45/45) (20/25): (23/22) (60.17 ± 2.85): (60.14 ± 4.81) NR DHI (30 mL ivgtt qd) 14d LVEF, ADRs 4
Geng and Hu (2016) RCT 63 (32/31) (23/9): (22/9) (62.7 ± 9.2): (61.5 ± 8.9) NR DHI (20 mL ivgtt qd) 7d IA, hs-CRP 5
Kong and Zhao (2014) RCT 60 (30/30) (16/14): (17/13) 67: 66 NR DHI (30 mL ivgtt qd) 10d ADRs 5
Ren and Jia (2013) RCT 40 (20/20) (27/13) (no details) NR CM (2003) DHI (40 mL ivgtt qd) 14d IHF, ICS, hs-CRP 5
Chen et al. (2010) RCT, Open-blinding 59 (29/30) (22/7): (21/9) (62 ± 5): (56 ± 12) GDMAMI (2001 CMA) DHI (20 mL ivgtt qd) 14d LVEF 5
Zeng et al. (2017) RCT, Open-blinding 120 (60/60) (38/22): (36/24) (65.13 ± 2.38): (64.38 ± 2.12) GDMAMI (2001 CMA) DHI (40 mL ivgtt qd) 14d TER, IHF, LVEF 5
Liu and Gu (2014) RCT 117 (58/59) (62/55) (no details) NR DTSTEMI (2010) DHI (30 mL ivgtt qd) 14d LVEF 5
Jin et al. (2019) RCT 117 (60/57) (39/21): (38/19) (57.7 ± 5.49): (57.4 ± 6.37) NR DHI (40 mL ivgtt qd) 14d LVEF 6
Wang et al. (2015) RCT 60 (30/30) (35/25) (no details) NR GDMAMI (2001 CMA) DHI (30 mL ivgtt qd) 7d IA, CK-MB, hs-CRP 5
Jin et al. (2011) RCT 60 (30/30) (16/14): (17/13) (59 ± 7): (60 ± 10) NR DHI (30 mL ivgtt qd) 14d IA, LVEF, CK-MB, hs-CRP 5
Hu et al. (2011) RCT 64 (32/32) (20/12): (23/9) (50.72 ± 8.63): (50.28 ± 5.66) NR DHI (20 mL ivgtt qd) 7d RBV, CFR, IA, IHF, CK-MB 5
Han et al. (2012) RCT 134 (76/58) (42/34): (32/26) (55.6 ± 12.5): (51.8 ± 13.6) GDMAMI (2001 CMA) DHI (20 mL ivgtt qd) 14d IA, IHF, ICS 5
Xu et al. (2015) RCT, Open-blinding 71 (36/35) (49/22) (no details) (65 ± 13): (63 ± 11) DTSTEMI (2010) DHI (40 mL ivgtt qd) 14d LVEF, CK-MB 5
Wu (2019) Non-RCT, Open-blinding 120 (60/60) NR (62 ± 2.5): (65 ± 3.5) NR DHI (30 mL ivgtt qd) 7d TER, hs-CRP 3
Cui and Wang (2014) RCT, Open-blinding 180 (90/90) (52/38): (54/36) (72.1 ± 6.5): (72.3 ± 5.8) GDMAMI (2001 CMA) DHI (30 mL ivgtt qd) 10d TER, hs-CRP 4
Qin et al. (2014) RCT 112 (56/56) (31/25): (30/26) (52.31 ± 11.24): (55.12 ± 10.52) DCAMI (1979 WHO) DHI (40 mL ivgtt qd) 7d CHF, CS, LVEF, CK-MB, hs-CRP 5
Zhang et al. (2019b) RCT, Open-blinding 80 (40/40) (46/34) (no details) (69.88 ± 3.16): (68.92 ± 3.08) DTSTEMI (2015) DHI (30 mL ivgtt qd) 7d CFR, IA 4
Wang et al. (2009) RCT 203 (116/87) (66/50): (45/42) (71.6 ± 8.6): (70.7 ± 8.1) NR DHI (30 mL ivgtt qd) 14d TER 5
Li et al. (2022a) RCT, Open-blinding 82 (41/41) (25/16): (24/17) (62.5 ± 4.6): (62.3 ± 4.5) NR DHI (20 mL ivgtt qd) 7d TER, BPM, CHF, LVEF, hs-CRP 5
Yan (2013) RCT 160 (80/80) (52/28): (55/25) (61.5 ± 18.4): (59.5 ± 19.5) CM (1980 NCPGIM) DHI (30 mL ivgtt qd) 14d TER 5
Jia et al. (2013) RCT 65 (33/32) (21/12): (19/13) (61.28 ± 13.76): (62.74 ± 11.19) CHD (2003) DHI (30 mL ivgtt qd) 14d TER, hs-CRP 5
Zhang et al. (2018) RCT, Open-blinding 110 (55/55) (33/22): (35/20) (61.9 ± 4.9): (62.5 ± 4.2) DCASTEMI DHI (20 mL ivgtt qd) 14d TER, CK-MB 5
Ji et al. (2016) RCT, Open-blinding 108 (54/54) (38/16): (36/18) (62.3 ± 6.5): (61.8 ± 6.7) GTNSTE-ACS (2012) DHI (40 mL ivgtt qd) 14d TER, IA, ICS, CK-MB 4
Zhou et al. (2010) RCT 65 (33/32) (18/15): (17/15) (64.5 ± 6.3): (62.5 ± 8.4) DCAMI (1979 WHO) DHI (30 mL ivgtt qd) 14d LVEF 5
Bai et al. (2009) RCT 80 (45/35) (30/15): (17/18) NR NR DHI (20 mL ivgtt qd) 10d TER 5
Qi et al. (2008) RCT 40 (20/20) (12/8): (13/7) (63.9): (68.1) NDCIHD (WHO) DHI (20 mL ivgtt qd) 20d TER 5
Han and Wang (2012) RCT 64 (32/32) (35/29) (no details) NR PIM (1997) DHI (20 mL ivgtt qd) 14d TER 5
Chen et al. (2016) RCT 80 (40/40) NR NR NR DHI (40 mL ivgtt qd) NR Hs-CRP 5
Huo et al. (2019) RCT 80 (40/40) (28/12): (26/14) (62 ± 4): (61 ± 6) TUDMI (2013) DHI (40 mL ivgtt qd) 14d IHF, CK-MB, hs-CRP 5
Zhang et al. (2010) RCT 214 (110/104) (142/72) (no details) NR NDCIHD (WHO) DHI (40 mL ivgtt qd) 14d IA 5
Zhang and Sun (2009) Non-RCT 100 (63/37) (no details) NR DCAMI (1979 WHO) DHI (30 mL ivgtt qd) 14d TER 4
Qin (2015) RCT 220 (110/110) (60/50): (64/46) (67.5 ± 1.9): (64.2 ± 3.1) NR DHI (30 mL ivgtt qd) 14d TER 5
Chen (2015) RCT 108 (54/54) (60/48) (no details) NR NR DHI (30 mL ivgtt qd) 14d TER 6
Lei (2014) RCT 110 (55/55) (30/25): (32/23) (68.8 ± 2.6): (66.8 ± 2.6) NR DHI (40 mL ivgtt qd) 14d TER 5
Feng (2021) RCT, Open-blinding 158 (79/78) (40/39): (42/36) (60.19 ± 1.38): (60.25 ± 1.2) NR DHI (ivgtt qd) 7d LVEF, ADRs 5
Shi (2018) RCT 80 (40/40) (25/15): (27/13) (68.27 ± 2.89): (67.12 ± 2.20) NR DHI (12 mL ivgtt qd) 14d TER 5
Jiang et al. (2011) Non-RCT 82 (42/40) (31/11): (30/10) (666.1 ± 11.6): (65.9 ± 10.8) DCCHD (WHO) DHI (30 mL ivgtt qd) 20d TER 4

RCT, randomized controlled trials; T, treatment group; C, control group; M, male; F, female; NR, not report; GDMAMI (2001 CMA), Guidelines for the diagnosis and management of acute myocardial infarction (2001 Chinese Medical Association); DCAMI (1979 WHO), Diagnostic criteria for acute myocardial infarction (1979 World Health Organization); NDCIHD (WHO), Nomenclature and diagnostic criteria for ischemic heart disease (World Health Organization); DCCHD (WHO), Diagnostic criteria for coronary heart disease (World Health Organization); PIM (1997), Practical internal medicine; UNMIDT (2007 CMA), Unstable angina and non-ST-segment elevation myocardial infarction diagnosis and treatment guidelines (2007 Chinese medical association); DTSTEMI (2010), Diagnosis and treatment of acute ST-segment elevation myocardial infarction (2010); DTSTEMI (2015), Diagnosis and treatment of acute ST-segment elevation myocardial infarction (2015); CM (2003), Cardiovascular Medicine; CHD (2003), Coronary heart disease; CM (1980 NCPGIM), Coronary heart disease (1980 National Cardiovascular Professional Group of Internal Medicine); GTNSTE-ACS (2012), Guidelines for diagnosis and treatment of non-ST elevation acute coronary syndrome (2012); DCASTEMI, Diagnostic criteria of acute non-ST elevation myocardial infarction; TUDMI (2013), Third universal definition of myocardial infarction (2013); TER, Total effective rate; ADRs, Incidence of adverse reactions; LVEF, Left ventricular ejection fraction; IA, Incidence of arrhythmia; CK-MB, Creatine kinase isoenzyme; hs-CRP, Hypersensitive C-reactive protein; IHF, Incidence of heart rhythm failure; ICS, Incidence of cardiogenic shock; RBV, Rate of blood vessels; CFR, Case fatality rate.

 Quality evaluation of study quality

A total of 38 studies (Qi et al., 2008; Bai et al., 2009; Wang et al., 2009; Zhang and Sun, 2009; Chen et al., 2010; Zhang et al., 2010; Zhou et al., 2010; Hu et al., 2011; Jiang et al., 2011; Jin et al., 2011; Han et al., 2012; Han and Wang, 2012; Chen and LIU, 2013; Jia et al., 2013; Ren and Jia, 2013; Yan, 2013; Cui and Wang, 2014; Kong and Zhao, 2014; Lei, 2014; Liu and Gu, 2014; Qin et al., 2014; Chen, 2015; Qin, 2015; Wang et al., 2015; Xu et al., 2015; Chen et al., 2016; Geng and Hu, 2016; Ji et al., 2016; Zeng et al., 2017; Shi, 2018; Zhang et al., 2018; Zhang et al., 2019; Huo et al., 2019; Jin et al., 2019; Li et al., 2019; Wu, 2019; Feng, 2021; Li et al., 2022) were included. All studies were RCT-s, with six studies using random number tables, one study using random coin tosses, one study using random sampling, and the remaining studies only referring to randomization. The schematic diagram of the risk assessment of bias included in the studies is shown in Figure 2, and the percentage of the risk assessment of bias is shown in Figure 3.

Schematic diagram of risk assessment of bias.

Proportion of risk assessment of bias.

 Outcomes Total effective rate

A total of 16 studies were included, with a heterogeneity test of p = 0.24 > 0.1, I2 = 19% < 50%, indicating that there was no heterogeneity in the included studies. The results of fixed-effect pooled effect size (Li et al., 2020) showed that the RR and 95% CI were 1.18 [1.14–1.12], p < 0.05, and the difference in results was statistically significant, as shown in Figure 4A. The sample size of the study is large, and its corresponding points are mainly close to the narrow area in the middle and upper part of the funnel. There is no heterogeneity or other bias in the results, as shown in Figure 4B. The results showed that the total effective rate of Danhong injection in the experimental group was higher than that of conventional treatment in the control group.

(A) Forest plot of Total effective rate. (B) Funnel plot of total effective rate.

 Incidence of arrhythmia

A total of 8 studies were included, with a heterogeneity test of p = 0.29 and I2 = 17%, indicating that there was no heterogeneous in the included studies were considered to be. The results of fixed-effect pooled effect size showed that the RR and 95% CI were 0.55 [0.46–0.65], p < 0.05, and the difference in results was significant and statistically significant, as shown in Figure 5A. The sample size of the study is large, and its corresponding points are mainly clustered in the narrow area of the upper funnel. There is no heterogeneity and other bias in the results, as shown in Figure 5B. The results showed that the incidence of arrhythmia in the experimental group was lower than that in the control group.

(A) Forest plot of arrhythmia incidence. (B) Funnel plot of arrhythmia incidence.

 Incidence of heart rhythm failure

A total of 8 studies were included, with a heterogeneity test of p = 0.97 and I2 = 0%, indicating that there was no heterogeneity in the included studies. The results of fixed-effect pooled effect size showed that the RR and 95% CI were 0.45 [0.30–0.70], p < 0.05, and the difference in results was significant and statistically significant, as shown in Figure 6A. The sample size of the study is large, and its corresponding points are mainly close to the middle and upper regions of the funnel. There is no heterogeneity or other bias in the results, as shown in Figure 6B. The results showed that the incidence of heart rhythm failure in the experimental group was lower than that in the control group.

(A) Forest plot of heart rate failure incidence. (B) Funnel plot of heart rate failure incidence.

 Incidence of cardiogenic shock

A total of 4 studies were included, with a heterogeneity test of p = 0.74 and I2 = 0%, indicating no heterogeneous in the included studies. The results of fixed-effect pooled effect size showed that the RR and 95% CI were 0.33 [0.11–1.04], p = 0.06 > 0.05, and there was no significant difference in the results, which was not statistically significant, as shown in Figure 7A. The number of studies was small and the sample size was small, and their corresponding points were mainly scattered in the middle and lower region of the funnel. There was no heterogeneity in the results, but there were other biases, as shown in Figure 7B.

(A) Forest plot of cardiogenic shock. (B) Funnel plot of cardiogenic shock.

 Left ventricular ejection fraction (LVEF)

A total of 11 studies were included, with a heterogeneity test of p < 0.00001 and I2 = 98% > 50%, indicating that there was heterogeneity in the included studies. Using the random-effects model, the pooled results showed that the MD and 95% CIs were 0.00 [0.00–0.00], p < 0.00001, and there was no significant difference in the results, which was not statistically significant, as shown in Figure 8A. The sample size of the study is large, and its corresponding points are mainly close to the narrow area in the upper part of the funnel. There are heterogeneity and other biases in the results, as shown in Figure 8B. The results showed that there was no difference in LVEF between the experimental group and the control group.

(A) LVEF forest diagram. (B) LVEF funnel diagram.

 Creatine kinase isoenzyme (CK-MB)

A total of 8 studies were included, with the heterogeneity test of p < 0.00001 and I2 = 99% > 50%, indicating that the included studies were heterogeneous. Using the random-effects model, the pooled results showed that MD and 95% CI were −0.81 [−0.92∼−0.69], p < 0.00001, and the difference in results was significant and statistically significant, as shown in Figure 9A. The sample size of the study is relatively scattered, and its corresponding points are distributed in the area outside the funnel plot. There are heterogeneity and other biases in the results, as shown in Figure 9B. The results showed that the CK-MB of the experimental group was lower than that of the control group.

(A) CK-MB forest diagram. (B) CK-MB funnel diagram.

 Hypersensitive C-reactive protein (hs-CRP)

A total of 10 studies were included, with a heterogeneity test of p < 0.00001 and I2 = 98% > 50%, indicating that the included studies were heterogeneous. Using the random-effects model, the pooled results showed that the MD and 95% CIs were −1.09 [−1.22∼−0.97], p < 0.00001, and the difference in results was significant and statistically significant, as shown in Figure 10A. The sample size of the study is relatively scattered, and the corresponding points are mainly close to the narrow area in the upper part of the funnel plot. There are heterogeneity and other biases in the results, as shown in Figure 10B. The results showed that the hs-CRP of the experimental group was lower than that of the control group.

(A) hs-CRP forest diagram. (B) hs-CRP funnel diagram.

 Incidence of adverse reactions

A total of 10 studies were included, with a heterogeneity test of p = 0.37 and I2 = 5%, and it was considered that there was no heterogeneity in the included studies. The results of fixed-effect pooled effect size showed that the RR and 95% CI were 0.37 [0.17–0.82], p < 0.05, and the difference in results was significant and statistically significant, as shown in Figure 11A. The number of studies is small, the sample size is large, and the corresponding points are mainly close to the middle and upper regions of the funnel. There is no heterogeneity and other bias in the results, as shown in Figure 11B. The results showed that the incidence of adverse reactions in the experimental group was lower than that in the control group.

(A) Forest plot of incidence of adverse reactions. (B) Funnel plot of incidence of adverse reactions.

 Discussion

Routine meta-analysis was performed on 38 RCTs according to the PRISMA guidelines. Revman software was used to perform statistical analysis of the effect size pooling. Meta-analysis results showed that DHI can not only improve the total effective rate of MI, but also reduce the incidence of arrhythmia, heart rate failure, CK-MB, hs-CRP and adverse reactions. It is suggested that DHI can effectively improve cardiac function, promote blood regurgitation and reduce the incidence of adverse reactions.

The overall effect of the test using the fixed-effect model showed that compared with the control group, the total effective rate was Z = 9.03 (p < 0.00001), confirming the effectiveness and safety of DHI in treating MI. The incidence of arrhythmia was Z = 6.83 (p < 0.00001), confirming the antioxidant and cardioprotective effects of Danshen on CVD (Bu et al., 2019). Pharmacological studies have shown that Safflower extract in DHI can reduce the incidence of arrhythmias by altering calcium overload of myocardial cells (Yu et al., 2022). The incidence of heart failure was Z = 3.60 (p = 0.0003), verifying that DHI can reduce cardiac load and improve myocardial tissue remodeling (Zheng et al., 2024). The incidence of adverse reactions was Z = 2.45 (p = 0.01), and the possible adverse reactions were related to the speed of DHI intravenous infusion and the patient’s allergy history (Gu X.L., 2022). The overall effect of random effect model test showed that CK-MB was Z = 13.76 (p < 0.00001), indicating that DHI has a certain improvement effect on myocardial injury. hs-CRP was Z = 17.29 (p < 0.00001), confirming that DHI had a certain inhibitory effect on inflammatory response. Our studies have proved that DHI has a significant therapeutic effect in the treatment of MI, which can effectively improve cardiac function, reduce the incidence of adverse reactions, and improve the overall living standard of patients.

MI, commonly known as a heart attack, is the main cause of death in patients with CVD (Chen et al., 2022), with the most common cause being a decrease or cessation of blood flow to the heart. At present, China is one of the countries with the heaviest burden of CVD in the world (Zhao, 2019), and the turning point of disease burden reduction has not yet appeared (Ma et al., 2023). Over the past 40 years, our understanding of the pathogenesis of MI has continued to evolve, allowing for new treatment strategies to dramatically improve survival rates (Saleh and Ambrose, 2018). With the frequent and successful application of traditional Chinese medicine (TCM) in the prevention of CVD, the efficacy of TCM in the treatment of CVD has attracted more and more attention (Liu et al., 2011). For example, in recent years, DHI has been a commonly used method for treating MI, and a large number of clinical trials have not only revealed the positive therapeutic effect of DHI on MI patients (Cui et al., 2021), but also reflected its multiple mechanisms of action on CVD. DHI can reduce the production of serum C-reactive protein (CRP) by inhibiting the activity of NF-κB in the vessel wall, thereby alleviating local inflammatory response (Fu et al., 2009). At the same time, DHI also has varying degrees of antihypertensive effect (Yang et al., 2024). In addition, DHI can also protect vascular endothelium, promote angiogenesis, inhibit thrombin activity, and promote thrombolysis (Li et al., 2018). Depending on the etiology and condition, MI can be divided into 5 types, among which type 2 is mainly caused by an increase in oxygen demand (eg, hypertension) or a decrease in oxygen supply (eg, coronary spasm or embolism, arrhythmias, hypotension) (Thygesen et al., 2018). Research has found that DHI is more effective in treating type 2 MI, and there is no significant difference in the treatment of recurrent MI (Hu et al., 2019). The potent and widely used role of DHI has been confirmed in pharmaceutical research. For example, DHI has a positive effect on inhibiting platelet aggregation, improving hemodynamic status, and protecting endothelial function in the treatment of MI patients (Liu et al., 2015). The studies included in this meta-analysis did not mention the side effects of DHI, but DHI may have some side effects, such as skin itching, flushing, rash, swelling at the injection site, nausea, and vomiting (Yu et al., 2018).

In clinical practice, TCM injections has been widely used in the treatment of MI in China and other Asian countries (Wang et al., 2018). As a composite endpoint of reinfarction and stroke, acute heart failure, and re-hospitalization for CVD, research on TCM injections has entered the stage of molecular biology (Gong et al., 2023). For the treatment of MI, TCM has the following principles of “treating the surface when urgent, and treating the root when slow”. The former is a life-saving measure, while the latter is the long-term maintenance of the stent to facilitate cardiac recovery. MI belongs to the category of heart pain, true heart pain, and chest pain in traditional Chinese medicine. In DHI, Danshen has the function of nourishing blood promote blood circulation and remove blood stasis, and it is the main medicine; Safflower has the effect of promoting blood circulation, removing blood stasis, and relieving pain, and is used as an auxiliary medicine. Therefore, DHI has the effects of promoting blood circulation and removing blood stasis, clearing meridians and soothing collaterals, and is used for chest pain caused by blood stasis and obstruction (Feng et al., 2019). DHI have been reported as a potential effective method for treating MI, but there are still many difficulties in its use, such as a lack of scientific evidence that has been rigorously evaluated by clinical trials, complex components, and unclear pharmacological mechanisms, which often hinder the promotion and use of TCM products in Western countries (Wang et al., 2018). At present, there are few systematic analysis studies on DHI in the treatment of MI, so it is necessary to systematically evaluate the efficacy and safety of DHI in the treatment of MI.

 Limitations

There are some limitations in this study. 1) Of the 38 included studies, only 8 provided detailed descriptions of the implementation of randomization. 2) Only 14 of the 38 studies explicitly mentioned the use of blinding. 3) There were differences in the experimental designs of the included studies. 4) Due to the low quality of the included studies, the widespread popularity of TCM and the preference of Chinese patients for TCM, it is difficult to distinguish whether the effect of DHI is confused by the effect of other TCM drugs, which will bring some bias to the meta-analysis. 5) Due to the small number of studies included in the statistical analysis and the small follow-up effect size, the upper and lower limits of 95% CI for the binary variable cardiogenic shock included 1, and the upper and lower limits of 95% CI for the continuous variable LVEF included 0, and the results showed no significant difference or statistical significance, so the conclusion of this study was not perfect.

 Conclusion

In summary, this study conducted a meta-analysis of the treatment of MI with Danhong injection, and concluded that Danhong injection had significant efficacy in the treatment of MI. Compared with conventional treatment, Danhong injection has a benefit in patients with MI in terms of total response rate, arrhythmias, heart failure, CK-MB and hs-CRP incidence, effectively improving cardiac function, while reducing the incidence of adverse effects and improving overall quality of life.

 Data availability statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

 Author contributions

SY: Methodology, Software, Writing–original draft. YW: Investigation, Methodology, Software, Writing–review and editing. HS: Investigation, Methodology, Validation, Writing–review and editing. TC: Investigation, Software, Validation, Writing–review and editing. HD: Validation, Writing–review and editing, Funding acquisition.

 Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China under Grant No. 82305081) the Zhejiang Provincial Natural Science Foundation of China under Grant No. LQ24H280010 and the administration of Traditional Chinese Medicine of Zhejiang Province of China under Grant No. 2023ZR010.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Bai X. Zhao P. Wang G. (2009). Efficacy of Danhong injection in treating acute myocardial infarction. Inn. Mong. J. Traditional Chin. Med 28 (04), 12. 10.16040/j.cnki.cn15-1101.2009.04.014 Bernardo W. M. (2017). PRISMA statement and PROSPERO. Int. Braz J. Urol. 43 (3), 383–384. 10.1590/S1677-5538.IBJU.2017.03.02 Bozkurt B. Coats A. J. S. Tsutsui H. Abdelhamid C. M. Adamopoulos S. Albert N. (2021). Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association. Eur. J. Heart Fail 23 (3), 352–380. 10.1002/ejhf.2115 Bu D. Su Z. Zou J. Meng M. Wang C. (2019). Study of the mechanism underlying therapeutic effect of Compound Longmaining on myocardial infarction using a network pharmacology-based approach. Biomed. Pharmacother. 118, 109234. 10.1016/j.biopha.2019.109234 Chen H. Cao Y. Shanshan Lin e. (2022). Meta-analysis and GRADE evaluation of Danred injection. J. Traditional Chin. Med. 63 (4), 332–340. 10.13288/j.11-2166/r.2022.04.008 Chen H. Chen Z. Yu F. Deng Y. Zhang S. Yan B. (2016). No reflow after PCI for acute myocardial infarction. Zhejiang J. Traditional Chin. Med. 51 (2), 921. 10.13633/j.cnki.zjtcm.2016.12.047 Chen H. Zhao L. Feng X. Chu R. Lv X. Wang S. (2010). Protective effectsof Danhong injection onmyocardium after reperfusion inpatientswith acutemyocardiuminfarction. Clin. Focus 32 (11), 1391–1392. 10.3969/j.issn.1002-7386.2010.11.022 Chen X. (2015). Clinical treatment study of 86 patients after infarction. Electron. J. Clin. Med. Literature 2 (25), 5251–5254. 10.16281/j.cnki.jocml.2015.25.056 Chen X. Liu X. (2013). Influence of danhong injection on serum levels of MCP-1 and H-fabp in NSTEMI patients. Chin. J. General Pract. 11 (09), 1378–1379. 10.16766/j.cnki.issn.1674-4152.2013.09.041 Cui X. Han S. Jin X. L. Wang Z. F. Zhang Q. Xie Y. M. (2021). Clinical comprehensive evaluation of Danhong Injection in treatment of stroke with blood stasis syndrome. Zhongguo Zhong Yao Za Zhi 46 (23), 6096–6104. 10.19540/j.cnki.cjcmm.20210930.506 Cui Y. Wang L. (2014). Effect of Danhong injection on oxidative stress and inflammation reaction in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Chin. J. Hosp. Pharm. 34 (3), 215–218. 10.13286/j.cnki.chinhosppharmacyj.2014.03.14 Dezawa M. Niizuma K. Tominaga T. (2019). Actualization of neural regenerative medicine by intravenous drip of donor-derived muse cells. Brain Nerve 71 (8), 895–900. 10.11477/mf.1416201372 Drucker A. M. Fleming P. Chan A. W. (2016). Research techniques made simple: assessing risk of bias in systematic reviews. J. Invest. Dermatol 136 (11), e109–e114. 10.1016/j.jid.2016.08.021 Feng H. (2021). Clinical effect exploration of danhong injection combined with routine treatment on patients with ST segment elevation acute myocardial infarction with percutaneous coronary intervention (PCI). World Latest Medicne Inf. 21 (66), 72–74. 10.3969/j.issn.1671-3141.2021.66.032 Feng X. Li Y. Wang Y. Li L. Little P. J. Xu S. W. (2019). Danhong injection in cardiovascular and cerebrovascular diseases: pharmacological actions, molecular mechanisms, and therapeutic potential. Pharmacol. Res. 139, 62–75. 10.1016/j.phrs.2018.11.006 Fu T. T. Wang C. J. Min C. Y. Huang X. H. (2009). Effects of danhong injection on experimental atherosclerosis rabbit model and its mechanism. Zhong Yao Cai 32 (11), 1720–1722. 10.13863/j.issn1001-4454.2009.11.028 Gao W. Bi D. Liu C. Shi X. Zhao F. Dai G. (2018). Tonifying Qi and activating blood circulation in terms of Traditional Chinese Medicine: their effects in patients with myocardial infarction. J. Tradit. Chin. Med. 38 (5), 726–732. 10.1016/s0254-6272(18)30911-7 Geng J. Hu Y. (2016). Clinical observation of the subsequent efficacy of Danhong injection in thrombolytic patients with acute ST elevation myocardial infarction. Pract. Clin. J. Integr. Traditional 16 (10), 15–16. 10.13638/j.issn.1671-4040.2016.10.008 Gong Y. Deng H. on G. X. a.s. (2023). Visual analysis of hot spots and trends in treatment of acute myocardial infarction with traditional Chinese medicine based on CiteSpace. Liaoning J. Traditional Chin. Med. 50 (8), 7–10. 10.13192/j.issn.1000-1719.2023.08.002 Gu X. L. (2022). Situation analysis of the revised contents of 23 Chinese medicine injection instructions. Chin. Med. Bull. 21 (6), 33–35. 10.14046/j.cnki.zyytb2002.2022.06.007 Han G. Liu W. Yang D. (2012). Effect of Danhong injection on myocardial reperfusion injury in acute myocardial infarction. People's Mil. Surg. 55 (6), 514–515. Han S. Wang B. (2012). Clinical observation of myocardial ischemia after acute myocardial infarction with Danhong injection. Proceeding Clin. Med. 21 (10), 750–751. 10.3969/j.issn.1671-8631.2012.10.014 He Q. Y. Yu X. Y. Xiao Z. Sun X. Zhu W. F. Yi X. Q. (2021). Comparison of the efficacy of danhong injections at different time-points during the perioperative period of acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 12, 643446. 10.3389/fphar.2021.643446 Higgins J. P. Altman D. G. Gøtzsche P. C. Jüni P. Moher D. Oxman A. D. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj 343, d5928. 10.1136/bmj.d5928 Himbert D. Juliard J. M. Steg P. G. (1995). Is coronary angioplasty the best treatment of acute myocardial infarction? Presse Med. 24 (38), 1831–1835. Hu D. Wang X. Wang B. Xie X. (2023). Observation on the clinical efficacy of different treatment methods for acute ST-segment elevation myocardial infarction. China J. Emerg. Resusc. Disaster Med. 18 (10), 1276–1279+1284. 10.3969/j.issn.1673-6966.2023.10.002 Hu J. Zhang W. Xie Y. Wang L. Nie X. Zhang Y. (2012). Meta-analysis of Shenmai injection treatment for acute myocardial infarction. China J. Chin. Materia Medica 37 (18), 2760–2767. 10.4268/cjcmm20121823 Hu N. Chen C. Wang J. Huang J. Yao D. Li C. (2021). Atorvastatin ester regulates lipid metabolism in hyperlipidemia rats via the PPAR-signaling pathway and HMGCR expression in the liver. Int. J. Mol. Sci. 22 (20), 11107. 10.3390/ijms222011107 Hu Z. Wang H. Fan G. Zhang H. Wang X. Mao J. (2019). Danhong injection mobilizes endothelial progenitor cells to repair vascular endothelium injury via upregulating the expression of Akt, eNOS and MMP-9. Phytomedicine 61, 152850. 10.1016/j.phymed.2019.152850 Hu Z. Xu Y. Du J. (2011). Study on the control effect of Danhong injection in thrombolysis of acute myocardial infarction for reperfusion injury. Health Vocat. Educ. 29 (8), 138–139. 10.3969/j.issn.1671-1246.2011.08.079 Huo Y. Chen S. Han X. (2019). Effect of danhong injection on acute myocardial infarction patients. J. Liaoning Univ. Traditional Chin. Med. 21 (0), 194–197. 10.13194/j.issn.1673-842x.2019.10.052 Ji C. Li P. Lu W. (2016). Clinical efficacy of the treatment of acute non ST-segment elevation myocardial infarction by danhong injection. Labeled Immunoassays Clin. Med. 23 (6), 680–682. 10.11748/bjmy.issn.1006-1703.2016.06.024 Jia F. Zhang K. Liu D. (2013). Clinical observation of 33 cases. Hebei J. Traditional Chin. Med. 35 (10), 1548–1549. 10.3969/j.issn.1002-2619.2013.10.061 Jiang Y. Zu D. Zhu G. Tu X. Zhou J. Jin Q. (2011). Observation of curative effect of the antiplatelet therapy of danhong injection among patients with acute myocardial infarction after percutaneous coronary stent implantation. Chin. Archives Traditional Chin. Med. 29 (10), 2281–2283. 10.13193/j.archtcm.2011.10.131.jiangym.073 Jin D. Wang H. Tang G. (2019). Effect of Danhong injection on serum retinol-binding protein 4 and cardiac function in patients with acute myocardial infarction. Chin. J. Traditional Med. Sci. Technol. 26 (2), 220–222. Jin Y. Li Z. Jin L. (2011). Myocardial protection effects of danhong injection in acute myocardial infarction patients receiving thrombolytic therapy for recanalization. Chin. General Pract. 14 (32), 3678–3680. 10.3969/j.issn.1007-9572.2011.32.007 Kandelouei T. Abbasifard M. Imani D. Aslani S. Razi B. Fasihi M. (2022). Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Mediat. Inflamm. 2022, 8732360. 10.1155/2022/8732360 Kong F. Zhao X. (2014). Effect of Danhong injection on the prognosis of patients with acute non-ST elevation myocardial infarction. Med. People 27 (4), 39. Krahn A. D. Tfelt-Hansen J. Tadros R. Steinberg C. Semsarian C. Han H. C. (2022). Latent causes of sudden cardiac arrest. JACC Clin. Electrophysiol. 8 (6), 806–821. 10.1016/j.jacep.2021.12.014 Lei Z. (2014). Efficacy of Danhong injection in patients with post-infarction angina. Prev. Treat. Cardiovasc. Dis. 20, 45–47. Li C. Cha L. Luo C. He X. (2022a). Application of Danhong injection after PCI of acute myocardial infarction. Guangming J. Chin. Med. 37 (5), 803–806. 10.3969/j.issn.1003-8914.2022.05.025 Li G. Pan M. Zhu D. (2019). Effects of the Danhong injection on cardiac function and indicators of reperfusion after PCI in patients with acute ST-segment elevation myocardial infarction. Clin. J. Chin. Med. 11 (08), 34–36. 10.3969/j.issn.1674-7860.2019.08.012 Li M. Zhou J. Jin W. Li X. Zhang Y. (2018). Danhong injection combined with t-PA improves thrombolytic therapy in focal embolic stroke. Front. Pharmacol. 9, 308. 10.3389/fphar.2018.00308 Li R. Chen H. Feng J. Xiao Y. Zhang H. Lam C. W. (2020). Effectiveness of traditional Chinese exercise for symptoms of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Int. J. Environ. Res. Public Health 17 (21), 7873. 10.3390/ijerph17217873 Li R. Wang T. Liu J. Yu S. Lou T. Ma B. (2022). Research on bioassay method of Danhong injection in inhibiting platelet aggregation in vitro . Chin. J. Pharmaceut. Analys., 1763–1770. 10.16155/j.0254-1793.2022.10.09 Lin L. Chu H. Hodges J. S. (2017). Alternative measures of between-study heterogeneity in meta-analysis: reducing the impact of outlying studies. Biometrics 73 (1), 156–166. 10.1111/biom.12543 Liu A. Gu H. (2014). Effect of Danhong injection on cardiac function and matrix metalloproteinases in patients with acute myocardial infarction. Shandong Med. J. 54 (21), 56–57. 10.3969/j.issn.1002-266X.2014.21.022 Liu H. X. Wang S. R. Lei Y. Shang J. J. (2011). Characteristics and advantages of traditional Chinese medicine in the treatment of acute myocardial infarction. J. Tradit. Chin. Med. 31 (4), 269–272. 10.1016/s0254-6272(12)60002-8 Liu M. Pan Q. Chen Y. Yang X. Zhao B. Jia L. (2015). Administration of Danhong Injection to diabetic db/db mice inhibits the development of diabetic retinopathy and nephropathy. Sci. Rep. 5, 11219. 10.1038/srep11219 Ma L. Wang Z. Jing Fan e. (2023). Interpretation of report on cardiovascular Health and diseases in China 2022. Chin. General Pract. 26 (32), 3975–3994. 10.12114/j.issn.1007-9572.2023.0408 Minamidate N. Takashima N. Suzuki T. (2022). The impact of CK-MB elevation in patients with acute type A aortic dissection with coronary artery involvement. J. Cardiothorac. Surg. 17 (1), 169. 10.1186/s13019-022-01924-5 Murphy A. Goldberg S. (2022). Mechanical complications of myocardial infarction. Am. J. Med. 135 (12), 1401–1409. 10.1016/j.amjmed.2022.08.017 Pitcher A. Spata E. Emberson J. Davies K. Halls H. Holland L. (2022). Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet 400 (10355), 822–831. 10.1016/S0140-6736(22)01534-3 Qi Y. Song L. Zhang M. (2008). Efficacy of Danhong injection on acute myocardial ischemia after acute myocardial infarction. China Med. Her. 5 (20), 93–94. 10.3969/j.issn.1673-7210.2008.20.057 Qin H. (2015). Analysis of the clinical treatment of angina pectoris after infarction. Cardiovasc. Dis. Electron. J. Integr. Traditional Chin. West. Med. 3 (06), 50–51. 10.16282/j.cnki.cn11-9336/r.2015.06.031 Qin L. Zuo H. Wang A. Sun X. (2014). Efficacy of Danhong injection in interventional therapy of ST segment elevation acute myocardial infarction. Shaanxi J. Traditional Chin. Med. 35 (6), 648–650. 10.3969/j.issn.1000-7369.2014.06.004 Ren Q. Jia G. (2013). Effect of Danhong injection on hypersensitive C-reactive protein in patients with acute myocardial infarction. Shaanxi J. Traditional Chin. Med. 34 (6), 651–652. 10.3969/j.issn.1000-7369.2013.06.007 Saleh M. Ambrose J. A. (2018). Understanding myocardial infarction. F1000Res 7, F1000. 10.12688/f1000research.15096.1 Shi J. (2018). To investigate the clinical effect of Danhong injection in the treatment of myocardial ischemia after acute myocardial infarction. Health Nutr. 28 (32), 94. 10.3969/j.issn.1004-7484.2018.32.139 Song B. An Z. Fan H. (2023). Investigation on the readiness for return-to-work of young adults patients with myocardial infarction and analysis of predictive factors. Med. Innovation China 20 (24), 143–147. 10.3969/j.issn.1674-4985.2023.24.034 Talebi S. S. Mohammad K. Rasekhi A. Mansournia M. A. (2019). Risk ratio estimation in longitudinal studies. Arch. Iran. Med. 22 (1), 46–49. Thygesen K. Alpert J. S. Jaffe A. S. Chaitman B. R. Bax J. J. Morrow D. A. (2018). Fourth universal definition of myocardial infarction (2018). Circulation 138 (20), e618–e651. 10.1161/CIR.0000000000000617 Wang C. Niimi M. Watanabe T. Wang Y. Liang J. Fan J. (2018a). Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries. Atherosclerosis 277, 136–144. 10.1016/j.atherosclerosis.2018.08.039 Wang D. Yang X. H. Zhang J. D. Li R. B. Jia M. Cui X. R. (2018b). Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord. 18 (1), 217. 10.1186/s12872-018-0948-4 Wang L. Wang G. Zhang Y. Wang Z. Tian G. (2015). Protection of Danhong injection on myocardium reperfusion injury after AMI thrombolysis. Jilin J. Chin. Med. 35 (2), 144–146. 10.13463/j.cnki.jlzyy.2015.02.013 Wang S. Huang D. Xu J. Duan H. (2022). Evaluation of drug-related problems in clinical application of danhong injection based on granada-II classification. Chin. Pharmaceut. Affair. 36 (11), 1315–1321. 10.16153/j.1002-7777.2022.11.015 Wang Z. Li Z. Ma L. Cao S. (2009). The clinical observation of Danheng injection for the treatment of myocardial infarction after the inter-vention. China Pract. Med. 4 (7), 46–47. 10.3969/j.issn.1673-7555.2009.07.028 Whiting P. F. Rutjes A. W. Westwood M. E. Mallett S. Deeks J. J. Reitsma J. B. (2011). QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern Med. 155 (8), 529–536. 10.7326/0003-4819-155-8-201110180-00009 Wu S. (2019). Effect of Danhong injection on oxidative stress and inflammatory response in patients with acute myocardial infarction after emergency percutaneous coronary intervention. Heal. Friend (23), 94–95. Xu X. Cui H. Yang J. Gui Y. Ren Y. (2015). Protective effect of Danhong injection on the ischemic myocardium after percutaneous coronary interven-tion for acute myocardial infarction. Mil. Med. J. Southeast China 17 (5), 451–454. 10.3969/j.issn.1672-271X.2015.05.001 Yan Y. (2013). Efficacy analysis of Danhong injection in 80 cases of early angina pectoris after myocardial infarction. Health Horiz. 21, 295. Yang J. Zhang Y. Ma T. Tian X. Zhao Y. (2023). Epidemic status, disease burden and prediction of cardiovascular diseases in China, 1990- 2019. Chin. General Pract. 27 (2), 233–244+252. 10.12114/j.issn.1007-9572.2023.0470 Yang X. Yang W. He S. Ye H. Lei S. (2024). Danhong formula alleviates endothelial dysfunction and reduces blood pressure in hypertension by regulating MicroRNA 24- Phosphatidylinositol 3-Kinase-Serine/Threonine Kinase- Endothelial Nitric Oxide Synthase axis. J. Ethnopharmacol. 323, 117615. 10.1016/j.jep.2023.117615 Yu L. Zhou C. Luo Z. Zeng W. Lai F. Han G. (2018). The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials. Lipids Health Dis. 17 (1), 106. 10.1186/s12944-018-0760-2 Yu T. Li Y. Yan M. Zhang Z. Yuan X. Li S. (2022). Mechanism of danhong injection in the treatment of arrhythmia based on network pharmacology, molecular docking, and in vitro experiments. Biomed. Res. Int. 2022, 4336870. 10.1155/2022/4336870 Zeng G. Wang C. Xue Y. Qin C. Kang X. (2017). Effect of Danhong injection on the serum IL-6 and IL-7 level in patients with acute myocardial infarction after percutaneous coronary intervention. J. Clin. Pathological Res. 37 (9), 1887–1893. 10.3978/j.issn.2095-6959.2017.09.020 Zhang C. Sun X. (2009). Observation of the efficacy of single red injection in acute myocardial infarction. Natl. Emerg. Crit. Care Med. 7 (1), 65–66. Zhang H. Ai J. Gao R. Li Y. Zhu H. Zheng X. (2018). Clinical efficacy analysis of Danhong injection in acute non-ST elevation myocardial infarction. Med. J. Chin. People's Health 30 (16), 62–64. 10.3969/j.issn.1672-0369.2018.16.030 Zhang H. Zheng S. Yuan X. Gao Z. (2010). Danhong injection treated 110 patients of acute myocardial ischemia. Shaanxi J. Traditional Chin. Med. 31 (10), 1297–1298. 10.3969/j.issn.1000-7369.2010.10.017 Zhang X. Yu X. Chen F. Zhu H. (2019). Guidelines for rapid diagnosis and treatment of acute coronary syndromes (2019). J. Clin. Emerg. 20 (04), 253–262. 10.13201/j.issn.1009-5918.2019.04.001 Zhang Y. Fu J. Xu a.B. (2019b). Effect of Danhong injection on ischemia-modified albumin and homocysteine levels and prognosis in patients with acute myocardial infarction without reperfusion therapy. Chin. J. Integr. Med. Cardio-Cerebrovascular Dis. 17 (19), 2974–2976. 10.12102/j.issn.1672-1349.2019.19.025 Zhao D. (2019). Characteristics and prevention needs of the current cardiovascular disease epidemic in China. Chin. Circulation J. 34 (04), 313–315. 10.1038/s41569-018-0119-4 Zheng Y. Zheng H. Guo Z. (2024). Comparative efficacy of five traditional Chinese medicine injections for treating heart failure with reduced and mildly reduced ejection fraction: bayesian network meta-analysis. Heliyon 10 (1), e23194. 10.1016/j.heliyon.2023.e23194 Zhou A. Huang Q. Yang Y. (2010). Analysis of the efficacy of Danhong injection in treating acute myocardial infarction with left heart insufficiency. Jiangxi Med. J. 45 (1), 34–35. 10.3969/j.issn.1006-2238.2010.01.021